Vor Biopharma Inc. (VOR) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Yaron Werber
TD Cowen, Research Division

Okay. Well, good morning, everybody, and thank you so much for joining us for the 46th Annual TD Cowen Healthcare Conference. I’m Yaron Werber from the biotech team, and it’s really a great pleasure to have with us today Vor Therapeutics and Jean-Paul Kress, the Chief Executive Officer.

Vor telitacicept is a BAFF/APRIL inhibitor with really promising data in both Phase III in gMG and Sjögren’s. The gMG data is going to come midyear and first patient in for the Phase III global Sjögren’s study is going to be by the end of the first half of this year. We’ve written extensively about both opportunities. gMG looks really promising based on the data, and we’re equally to, frankly, even more excited about Sjögren’s, which is frankly a big white space.

So Jean-Paul, thanks so much for joining us. We appreciate it. We’ll do a presentation and then Q&A.

Jean-Paul Kress
Chairman & CEO

Thank you, Yaron, and good morning, everyone.

Yaron Werber
TD Cowen, Research Division

Very pleased to be here and to update you — presentation. Just trying to retreat the slides. So very pleased to be here and to tell you about our progress at Vor Bio. Thank you. I’ll be making forward-looking statements during this presentation. This is our disclosure slide.

At Vor, our ambition is to significantly improve the standard of care in autoimmune disease. And for doing that, in 2025, in June, we in-licensed one of the most exciting opportunities in autoimmune, a late-stage asset called telitacicept. Telitacicept comes from the China biotech innovation engine. It’s RemeGen, our partner there, who has